Market Intelligence, Clinical Progress, and High-Purity Reagents for ROS-Modulating Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NOX1 drug discovery. Each component is designed to address critical challenges in membrane protein targeting and isoform selectivity.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NOX1 Recombinant Protein / Complex (full-length, mutant & domain variants available). Sequence Verified. High purity (>95%), Endotoxin <1EU/ug. HEK293 expressed. | View NOX1 Products |
| Gene Delivery | NOX1 Lentivirus Premade Particles. Full-length ORF for stable cell lines. HEK293T packaged, titer >10^7 TU/mL. Preserves native membrane conformation and glycosylation. | View NOX1 Products |
| Benchmark Ab | Anti-NOX1 Control Antibody (Reference Sequence). Recombinant positive control for detection and assay baseline. | View NOX1 Products |
| Validator | NOX1 siRNA Set (3 unique sequences). For knockdown verification and assay specificity confirmation. Sequence verified. | View NOX1 Products |
| Isoform Selectivity: NOX2 | NOX2 (CYBB) Lentivirus / Membrane Prep. Critical for counter-screening; phagocyte NADPH oxidase isoform. | View NOX2 Products |
| Isoform Selectivity: NOX4 | NOX4 Lentivirus / Membrane Prep. Constitutively active isoform; essential for selectivity profiling. | View NOX4 Products |
| Regulatory Partner | CYBA (p22phox) Recombinant Protein / Co-expression Lentivirus. Essential for NOX1 maturation, stability and membrane localization. High-purity for binding assays. | View CYBA Products |
| Pathway Partner | RAC1 Wild-Type & Q61L Mutant Protein. GTPase required for NOX1 activation. Mutant for constitutive activity assays and mechanism-of-action studies. | View RAC1 Products |
| Accessory Proteins | NOXA1 and NOXO1 Recombinant Proteins. For in vitro reconstitution of NOX1 activation complex. | View NOXA1 Products (request) |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (NOX1 vs NOX2 vs NOX4) | Human NOX1, NOX2, NOX4 ortholog stable cell lines available. Sequence verified, expression confirmed by qPCR and Western blot. Panel for cross-reactivity and selectivity assays. |
| Complex Membrane Protein Conformation | Lentivirus-based stable cell lines preserve native folding, glycosylation and membrane topology. HEK293 expression system with rigorous QC. |
| p22phox Dependency / Complex Activation | CYBA co-expression lentivirus system; high-purity CYBA, NOXA1, NOXO1 recombinant proteins for reconstitution and PPI studies. |
| Lack of Specificity Controls | Validated NOX1 siRNA set and anti-NOX1 reference antibody included for target engagement confirmation. Orthogonal specificity checks. |
| False Positive Mitigation | Assay-ready controls (positive and negative) and sequence-verified reagents to reduce artifact signals. |
Live NOX1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NOX1 therapeutics is intensifying, with major players shifting focus from pan-NOX inhibitors to isoform-selective modulation and emerging targeted degraders. First-generation dual NOX1/NOX4 inhibitors (such as Setanaxib from Genkyotex) are advancing in fibrotic and cancer immunotherapy trials, while the next wave targets NOX1-specific blockade to avoid NOX2-mediated immunosuppression. High-value indications include colorectal cancer (NOX1-driven ROS promoting tumor angiogenesis), inflammatory bowel disease (IBD), diabetic nephropathy, and idiopathic pulmonary fibrosis. The strategic shift towards extreme isoform selectivity and rational combination with chemotherapy or checkpoint inhibitors is expected to dominate R&D over the next 3-5 years.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor (Pan-NOX) | Genkyotex (GKT137831), Sanofi | Idiopathic Pulmonary Fibrosis, Diabetic Nephropathy | Isoform Selectivity Panel (NOX1 vs NOX2 vs NOX4). Stable cell lines expressing individual isoforms are essential. |
| Small Molecule Inhibitor (NOX1-Selective) | Preclinical Biotech | Colorectal Cancer, IBD | NOX1/p22phox Interaction Assay. Requires full-length membrane-integrated protein and downstream ROS detection. |
| Monoclonal Antibody | Preclinical biotech | Inflammation | Binding Assay. Need lentivirus-generated cell lines with native NOX1 conformation for epitope screening. |
| Peptide Inhibitor | Academic / Spin-offs | Ischemia Reperfusion, Vascular Inflammation | Functional Screening (ROS inhibition). High-purity target protein or membrane preps required. |
| Combination Therapy (with IO) | Oncology Consortiums | Anti-PD1 resistant tumors | ROS Detection in co-culture systems. NOX1-specific readouts needed for mechanism validation. |
NOX1 Protein Characteristics and Key Mutations
NADPH oxidase 1 (NOX1, UniProt Q9Y5S8) is a membrane-associated catalytic subunit that generates superoxide. It contains two key functional domains: a Ferric oxidoreductase domain and an FAD-binding FR-type domain, both essential for electron transfer and ROS production. Clinically relevant mutations have been reported in dbSNP (rs2071756) and in patients with very early onset inflammatory bowel disease (VEO-IBD). Two missense variants (VAR_075548 and VAR_061176) are of uncertain significance but highlight the link between NOX1 dysfunction and intestinal inflammation. Understanding these structural and mutational aspects is critical for designing targeted assays and interpreting functional data in drug discovery.